{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-012858","form_type":"8-K/A","ticker":"IVF","cik":"0001417926","company_name":"INVO Fertility, Inc.","filed_at":"2024-04-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.326057+00:00","generated_at":"2026-06-04T03:26:22.055053+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"INVO Bioscience enters equity line with Triton Funds for up to $850k, issues warrants at $2.00","bullets":["Purchase Agreement to sell up to 1M shares at $0.85/share, gross proceeds up to $850k, expires Dec 31, 2024.","Private placement warrants to buy 1M shares at $2.00/share, exercisable for 5 years from issuance.","Stockholder approval may be required if issuances exceed 523,344 shares (19.9% of outstanding) under Nasdaq rules.","Warrants are unregistered; cashless exercise permitted if no effective registration statement.","Triton's beneficial ownership limited to 9.99% of outstanding common stock."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-012858","json":"https://secwatch.observer/filing/0001493152-24-012858.json","markdown":"https://secwatch.observer/filing/0001493152-24-012858.md","text":"https://secwatch.observer/filing/0001493152-24-012858.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1417926/000149315224012858/0001493152-24-012858-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1417926/000149315224012858/form8-ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T03:26:22.055053+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"255244880e15a66b5e33b62f3cf93915123885e6","claim":"INVO Fertility, Inc. entered into Purchase Agreement with Triton Funds LP valued at up to $850,000 (effective 2024-03-27).","evidence_excerpt":"On March 27, 2024, INVO Bioscience, Inc., a Nevada corporation (the “ Company ”) entered into a purchase agreement (the “ Purchase Agreement ”) with Triton Funds LP (“ Triton ”), pursuant to which the Company agreed to sell, and Triton agreed to purchase, upon the Company’s request in one or more transactions, up to 1,000,000 shares of the Company’s common stock, par value $0.0001 per share, providing aggregate gross proceeds to the Company of up to $850,000.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315224012858/0001493152-24-012858-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Triton Funds LP"},{"label":"Value","value":"up to $850,000"},{"label":"Effective","value":"2024-03-27"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}